.png)
.png)
Membership directory
We represent over 300 companies. Our members include start-up, emerging and more established bioscience companies, pharmaceutical companies, academic, research and philanthropic organisations, and service providers to the biosciences sector.
Find our members using company name keywords or locations (click on the tabs above and use the search boxes), or use the filters on the right to narrow down your results.
Several of our member companies have sites in multiple locations and so are listed multiple times in the directory. Use the locations tab to view the different sites on the map.
Influence, connect and save with the BIA. Find out about how we can work together.
3M helps build better, more efficient manufacturing processes, develop technologies that allow process compression and enhanced product recovery that leads to improved process economics.
A.A. Thornton & Co. is a leading intellectual property law firm, based in London and serving a global client base.
AbbVie combines the focus and passion of a leading-edge biotech with the expertise and capabilities of a long-established pharmaceutical leader to develop and market advanced therapies that address some of the world’s most complex and serious diseases.
Abcodia is a clinical stage company engaged in the development of novel algorithms for the early detection of cancer.
Abingworth is an international investment group dedicated exclusively to the life sciences and healthcare sectors. We invest across all stages of company development including early and late-stage venture financing, growth equity and public companies.
Abzena enables the development of better treatments for patients, through its work with the top biopharmaceutical companies and academic groups worldwide.
Acacia Pharma develops and commercialises supportive care products for post-surgical and cancer patients. The company addresses these opportunities through repurposing.
Achilles Therapeutics is a biopharmaceutical company developing personalised T cell therapies targeting neoantigens
Adaptate Biotherapeutics is developing therapeutic antibodies to harness the unique power of gamma delta T cells for next generation immunotherapy.